Kornimate/medical-research-clean huggingface dataset:
effects of cyclooxygenase (cox) 1-2 inhibitors on prevention of rocuronium injection pain

Conditions: Injection Site Irritation

Summary: purpose : the aim of the study is to investigate the effects of cox inhibitors as a rescue agent against the rocuronium pain methodology : sixty patients enrolled for the general anesthesia enrolled in this study. patients were allocated into two groups (group 1: dexketoprofen group, group 2: control group) .pain was evaluated by during rocuronium injection, patients were scored by a scale showed below. 0;no movement response to injection 1. mild movement response to injection 2. hand withdrawal response to injection 3. arm withdrawal response to injection investigators also evaluated the pain with 2 questions when the patient was in the recovery room. question 1.what was the last feeling before participants fall into sleep? question 2. did participants feel any pain on participants's hand during medication injection for anesthesia?

purpose : rocuronium bromide is a painful agent while general anesthesia induction. the aim of the study is to investigate the effects of cox inhibitors as a rescue agent against the rocuronium pain methodology : sixty patients enrolled for the general anesthesia enrolled in this study. patients were allocated into two groups (group 1: dexketoprofen group, group 2: control group) .pain was evaluated by during rocuronium injection, patients were scored by a scale showed below. 0;no movement response to injection 1. mild movement response to injection 2. hand withdrawal response to injection 3. arm withdrawal response to injection investigators also evaluated the pain with 2 questions when the patient was in the recovery room. question 1.what was the last feeling before participants fall into sleep? question 2. did participants feel any pain on participants's hand during medication injection for anesthesia?

Eligibility criteria:
inclusion criteria: * non allergic to dexketoprofen * 18-60 years old * american society of anesthesiologists(asa) 1-2-3 * 70-90 kg weigh exclusion criteria: * patients with psychiatric and mental problems

Keywords: dexketoprofen, pain, rocuronium
choice switching and autism

Conditions: Autism Spectrum Disorder (ASD)

Summary: the study aims to replicate and clarify a recently observed phenomenon whereby individuals with autism spectrum disorder (asd) switch between options in a repeated task to a greater extent than healthy controls do. in a meta-analysis a large effect size was found (.37) yet because the effect was noisy in different studies it was not statistically significant. the investigators seek to first examine a very large population through an internet mediated platform. the sample size will be about the size of all of the previous studies that examined this issue together. secondly, the investigators wish to understand the discrepancy between this choice switching phenomenon and the recorded tendency of asd individuals to avoid changing choices. first, the investigators will administer the task in which the effect was found (the iowa gambling task) for a longer duration than previously and evaluate whether asd individuals show increased choice switching in the first blocks of trials but reduced switching following more experience. secondly, the investigators will administer an additional block of trials without feedback in which participants will not be able to go through a learning process. the investigators predict that this will reduce (and possible flip) the tendency of individuals with asd to switch choices more often.


Eligibility criteria:
inclusion criteria: * asd group - diagnosed with asd * control - no asd diagnosis: within age and education range of the asd group. exclusion criteria: * demographics: under 18 years of age. * mental health: self reported brain injury and neurological disorder (besides autism).

Keywords: autism spectrum disorder decision making
mp0250 darpin® protein plus osimertinib in patients with egfr-mutated nsclc

Conditions: EGFR-mutated NSCLC (Disorder)

Summary: the purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (pk), immunogenicity and biological activity of the mp0250 darpin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with egfr mutated, advanced, non squamous nsclc after tumor progression on osimertinib and on or after the most recent therapy. mp0250 is a multi-darpin® protein with three specificities, able to simultaneously neutralize the activities of vascular endothelial growth factor (vegf) and hepatocyte growth factor (hgf) and also to bind to human serum albumin (hsa) to give an increased plasma half-life and potentially enhanced tumor penetration.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed metastatic or unresectable locally advanced non-squamous nsclc with documented egfr mutation-positive disease 2. radiologically documented disease progression on previous osimertinib treatment. 3. radiologically documented disease progression on or after most recent antitumor therapy. 4. measurable disease according to recist 1.1. 5. eastern cooperative oncology group (ecog) performance status (ps) 0 2. 6. men and women ≥18 years old on the day of signing informed consent. 7. adequate hematological, hepatic and renal function prior to first dose 8. serum albumin concentration ≥30 g/l 9. potassium and magnesium within normal range exclusion criteria: 1. necrotic tumors or tumors close to large blood vessels that may impose an increased bleeding risk when treated with anti-vegf agents. 2. second malignancy that is currently clinically significant or required active intervention during the period of 12 months prior to screening, except early stage non-melanoma skin cancer treated with curative intent. 3. known pre-existing interstitial or inflammatory lung disease. 4. clinical signs of or documented leptomeningeal carcinomatosis. features such as headache, nuchal rigidity, and photophobia may indicate meningeal involvement. 5. known brain metastases who are clinically unstable 6. prohibited anti-nsclc therapies and not having recovered from related aes to common terminology criteria for adverse events (ctcae) grade ≤1 7. any investigational drug within 28 days prior to study treatment. 8. current participation in any other interventional clinical study (except survival follow up). 9. neuropathy as residual toxicity after prior antitumor therapy grade \>2 10. patients taking medications that have the potential to prolong the qt interval 11. significant cardiac abnormalities 12. uncontrolled hypertension 13. significant risk for bleeding 14. active or recent thrombolic events

Keywords: darpin®protein mp0250 vegf hgf nsclc egfr mutated osimertinib
ip3r modulation by cancer genes in mesothelioma

Conditions: Malignant Mesothelioma

Summary: obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction


Eligibility criteria:
inclusion criteria: * suspicion of mesothelioma * referral for diagnostic thoracoscopy exclusion criteria: * contra-indication for thoracoscopy
transcultural and psychometric validation of sushi and hoos-12 scores in patients with coxofemoral pathologies

Conditions: Coxofemoral Pathologies

Summary: the management of coxofemoral pathologies is constantly increasing. in addition to degenerative hip pathology, the orthopedic surgeon is now confronted with pathologies such as femoro-acetabular conflict, pathologies of the gluteus medius and pathologies of the labrum whose early management limits arthritis degeneration. these pathologies are mainly encountered in young subjects (\<60 years). self-questionnaires play an important role in understanding patients' point of view on the impact of their coxofemoral pathologies and also allow an assessment of their condition after treatment. for the evaluation of coxofemoral pathologies in the young subject (\<60 years) the super simple hip score (sushi-score) was developed and validated. in the elderly subject with hip osteoarthritis, the hoos score has the advantage of specifically measuring pain, symptoms, function and quality of life, but is made up of 40 items and is often considered rather heavy to submit. however, it has recently been simplified and the hoos-12 (hoos score with 12 items) has been developed and validated. these two scores are useful in current clinical practice but they are only validated in english.


Eligibility criteria:
inclusion criteria: * adult patient (age greater than or equal to 18 years old), * patient with coxofemoral pathology, * patient having been informed of the research, * patient agreeing to participate in the study. exclusion criteria: * minor patient, * pregnant woman, * patient out of state to agree to participate in the study, * patient unable to answer a self-assessment questionnaire, * patient under justice, guardianship or curatorship, * patient who refused to participate in the study.

Keywords: coxofemoral pathologies self assessment questionnaire super simple hip score (sushi-score) hip disability and osteoarthritis outcome score (hoos score) transcultural validation psychometric validation hip and groin score (hagos)
haic sequential tae combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma

Conditions: Intrahepatic Cholangiocarcinoma

Summary: this is a single center, single arm, phase ii, prospective study to evaluate the safety and effectiveness of haic combined with tae plus an ici and an tki in adult patients (aged ≥18 years) with unresectable intrahepatic cholangiocarcinoma.

compared with systemic intravenous chemotherapy, hepatic arterial infusion chemotherapy(haic) has the advantages of increasing local drug concentration and reducing systemic toxic and side effects. all patients were treated with haic (oxaliplatin and raltitrexed ). surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time； tislelizumab was given 200mg every 3 weeks. the treatment continued until the patient developed the disease or met the other criteria for terminating the study.

Eligibility criteria:
inclusion criteria: 1. written informed consent for the trial. 2. aged ≥18 years. 3. histologically confirmed intrahepatic cholangiocarcinoma. 4. no other previous systematic treatment for btc. 5. at least one measurable lesion (recist 1.1). 6. eastern cooperative oncology group performance status 0 or 1. 7. life expectancy of 3 months or greater. 8. child-pugh classification score ≤7. exclusion criteria: 1. recurrent patients. 2. eastern cooperative oncology group performance status ≥ 2. 3. life expectancy of less than 3 months. 4. child-pugh classification score \> 8. 5. history of hepatic encephalopathy or liver transplantation. 6. known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation. 7. symptomatic pleural effusion, ascites, and pericardial effusion that require drainage. 8. portal vein tumor thrombus (pvtt) involves both the main trunk and contralateral branch or upper mesenteric vein. inferior vena cava tumor thrombus. 9. prior treatment with immunotherapy agents (including, anti-pd-1, anti-pd-l1, anti-ctla4, etc.). 10. history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis. 11. the researcher considers it inappropriate to enter this study.
dose-confirmatory bridging study in total hip replacement

Conditions: Venous Thromboembolism

Summary: the objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (vte) in japanese patients undergoing elective total hip replacement (thr) and to confirm the extrapolability of global data to japanese patients by comparing with data from overseas phase ii study (odixa-od.hip - study 11527).


Eligibility criteria:
inclusion criteria: * male and female patients aged 20 years or above * patients undergoing elective thr (the first replacement of the applicable hip joint) * patients' written informed consent to participation after receiving detailed verbal and written information on any study specific procedures in advance exclusion criteria: * planned, staged major orthopedic surgery within 3 months prior to elective thr or during this study * history of clinically significant active bleeding (e.g. intracranial bleeding, gastrointestinal bleeding\*), or high bleeding risk \*: within 3 months prior to elective thr for gastrointestinal bleeding * subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk * severe impaired renal function (clcr calculated by cockcroft-gault formula: \<30 ml/min) * conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media) * ongoing anticoagulant therapy (e.g. warfarin, heparins and factor xa inhibitors other than study medication) that cannot be stopped (in the opinion of the investigator/sub investigator) * subjects for whom epidural catheters are expected to be left in for longer than 18 hours post-operatively * planned intermittent pneumatic compression during treatment period

Keywords: venous thromboembolism prevention othopaedic surgery
evaluating clinical evaluation tools for predicting risk of complications after hematopoietic stem cell transplant

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this study evaluates whether clinical evaluation tools such as the six-minute walk test, hand grip strength test, and gait speed test, are useful in predicting risk of complications in patients undergoing hematopoietic stem cell transplants (hct). being able to predict who is at increased risk of post-hct complications can help better inform patients and providers on the risks and benefits of undergoing hct and determine whether certain patients should have closer post-hct monitoring due to an increased risk of complications.

primary objective: i. to develop novel pre-transplant tools for determining risk of post-hct pulmonary complications. outline: this is an observational study. patients undergo a clinical evaluation consisting of a six-minute walk test, hand grip strength test, and gait speed test on study. patients' medical records are also reviewed for a year on study.

Eligibility criteria:
inclusion criteria: * adult patients (age \>= 18 years old) * undergoing evaluation for autologous or allogeneic bone marrow transplant (hct) at mayo clinic rochester * scheduled for pre-hct pulmonary function test by the primary team exclusion criteria: * limited mobility requiring use of gait aid or wheelchair * fall risk
efficacy and safety of electroacupuncture on lumbar disc herniation with radiculopathy

Conditions: Lumbar Disc Herniation; Radiculopathy Lumbar

Summary: lumbar disc herniation with radiculopathy (ldhr) is the local displacement of the intervertebral disc and its contents beyond the edge of the normal intervertebral disc space, resulting in pain, weakness or numbness in the muscle or dermatomal distribution area. electroacupuncture is based on obtaining the needling sensation manually and applying electrical stimulation of different frequencies and intensities, aiming to enhance the intensity of acupoint stimulation to improve the effect. as a kind of acupoint stimulation therapy, electroacupuncture has shown analgesic effects in animal experiments. however, at present, the clinical evidence of electroacupuncture applied in the treatment of ldhr is still insufficient. therefore, this randomized, single-blind, sham electroacupuncture controlled trial aims to evaluate the efficacy and safety of electroacupuncture as a treatment for ldhr.


Eligibility criteria:
inclusion criteria: 1. aged from 18 to 70 years old. 2. with intervertebral disc protrusion confirmed by a mri or ct, accompanied by radicular pain in the lower extremities. 3. with a nrs score ≥ 4 points for both low back pain and leg pain, and the pain lasts for at least 3 months; 4. voluntarily participating the trial and signing the informed consent form. exclusion criteria: 1. previous surgical treatment of the spine. 2. received any physical therapy for lumbar disc herniation within the recent 3 months. 3. complicated with diseases that can cause low back and leg pain. 4. symptomatic foraminal stenosis caused by severe degenerative diseases, accompanied by severe nerve injuries. 5. previous severe mental illness, organ failure, or malignant tumor. 6. planned spinal surgery or other major surgeries within the next 3 months. 7. pregnancy or lactation.

Keywords: electroacupuncture radiculopathy sham control randomized controlled trial lumbar disc herniation
prevalence and variables associated with depression in subjects with chronic wounds using phq-9 as a screening tool

Conditions: Wound

Summary: the objective of the study is to complete a retrospective chart review of subjects who were treated at the wound care clinic at methodist dallas medical center, presented for treatment between june 2018 and february 2019, and were administered the phq-9. the study aims to measure the prevalence of depression in this sample, feasibility of using phq-9 in this patient population, and identifying variables and functional impairment associated with clinically significant depression.

the study will review medical records of new patients who presented to the wound care center at methodist dallas medical center between june 2018 and february 2019. these patients were all administered phq-9 as part of a quality improvement project. the medical records included for analysis will be from male and female patients aged 18 years or older. the medical records will be reviewed for the following information: general demographics, information including age, sex, ethnicity, race, phq-9 score (total and individual items), medical conditions, wound history, past medical history, general symptoms, abuse and suicide risk, activities of daily living, motivation assessment, mental status, and pain ratings. this information will be used to measure the prevalence of clinically significant depression in the sample, which is the primary aim. we will also use the data to establish factors and variables correlated with the presence and severity of clinically significant depression.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. received care at the wound care center at methodist dallas medical center between june 2018 and february 2019 3. completed a phq-9 form at the time of initial evaluation/examination exclusion criteria: 1. patients less than 18 years of age will be excluded from the study
development of an eortc immune checkpoint inhibitor-specific quality of life item list: phase 1 & 2

Conditions: Cancer; IMMUNE CHECKPOINT INHIBITOR; Quality of Life

Summary: over the past 20 years, the views and experiences of patients in the field of oncology (through patient-reported outcomes, proms) have become increasingly important. when used in clinical trials, proms contribute to better detection and are used in clinical trials to improve the detection and management of treatment side effects. the health-related quality of life assessments are widely used in oncology research, and the development of reliable and valid measurement instruments has become a major challenge. in this context, health-related quality of life in cancer patients covers various aspects (functional status, physical or psychological symptoms) and several cancer-specific measurement instruments have been developed, including the eortc qlq-c30 quality of life questionnaire. among the different therapies used to treat cancers, immunotherapy with immune checkpoint inhibitors has been gaining momentum in recent years. commonly used to treat a wide variety of cancers, it also has a wide range of known side effects. however, little is known about the health-related quality of life of patients patients who receive this therapy: specific self-questionnaires are almost non-existent or inadequate, not covering all the effects related to immune checkpoint inhibitor toxicity. as for the data currently collected, they suffer from methodological problems. in view of the increasing use of immune checkpoint inhibitors in cancer treatment, their known side effects and the lack of valid questionnaires specific to these treatments, it appears important to provide a valid questionnaire to take into account these impacts on the quality of life of patients.


Eligibility criteria:
patients : inclusion criteria: * provision of written informed consent to participate in the study * has been diagnosed with cancer * either currently receiving, or has received in the previous 12 months, one of the following: * an anti-pd-1 or anti-pdl-1 agent as the sole immune checkpoint inhibitor treatment (at least three cycles) * an anti-pd-1 or anti-pdl-1 agent in combination with an anti-ctla-4 agent (at least one cycle) * cytotoxic chemotherapy and an anti-pd-1 or anti-pdl-1 agent (at least three cycles) * aged ≥18 years exclusion criteria: * has an additional primary cancer for which they are receiving systemic therapy * cognitive impairment which presents an obstacle to the completion of questionnaires or an interview * poor command of the locally dominant language, or an inability to read questions * \[phase 1b only\] was interviewed for phase 1a healthcare professionals : inclusion criteria: * holds, or has held, a professional clinical position which involves working directly with cancer patients who are in receipt of immune checkpoint inhibitors * is a medical oncologist, nurse specialist (or equivalent), psychologist, or social worker exclusion criteria: • has met the inclusion criteria for \<1 years
genetic analysis between charlotte's web responders versus non- responders in a dravet population

Conditions: Dravet Syndrome

Summary: there is tremendous curiosity about medical marijuana and the treatment of epilepsy. in a specific genetic epilepsy known as dravet syndrome, a mutation occurs affecting the scn1a gene. a specific strain of marijuana known as charlotte's web, available in colorado, may have activity in this catastrophic epilepsy syndrome. anecdotal reports suggest both success and lack of response with this therapy. genetic analysis of the differences between dravet responders and non-responders may prove useful for identifying patients likely to be helped by this therapy, as well as shed light on the putative mechanisms by which marijuana may exert any antiepileptic effect.


Eligibility criteria:
inclusion criteria: * age 1-50 with gene confirmed dravet syndrome * uncontrolled epilepsy, having failed at least 2 prior treatments (including appropriate anti-epileptic drugs, ketogenic diet, vagus nerve stimulation therapy) * seizure frequency should be more than 2 visually countable motor seizures per week (tonic clonic, tonic, clonic, myoclonic, or astatic) * care providers able to identify convulsive seizures, drop attacks, or tonic seizures, or any combination of countable seizure types * self- seeking therapy with charlotte's web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy * care provider able to complete seizure count diary * able to obtain oral swab sample from subject with dravet syndrome * agree to forfeit any right to results of genetic analysis exclusion criteria: * subjects having non-epileptic seizures that are not distinguishable from epileptic seizures by the care provider * prisoners * pregnant women * failure to forfeit right to results of genetic analysis

Keywords: dravet syndrome cannabidiol therapy charlotte's web